Agios Pharmaceuticals (AGIO)
(Delayed Data from NSDQ)
$46.55 USD
-0.83 (-1.75%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $46.57 +0.02 (0.04%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Agios Pharmaceuticals, Inc. [AGIO]
Reports for Purchase
Showing records 121 - 140 ( 312 total )
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Two Studies at ASH Corroborate Previous Findings for Mitapivat; Reiterate Buy and $95 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Weekly Retail Sales Tracker for Hem. Malignancies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: Research Department
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended November 19
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: Research Department
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended October 29.
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Largely Pro Forma 3Q21 Belies Great Things to Come for Agios; Reiterate Buy and Slight PT Raise to $95
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended October 22.
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: Research Department
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended October 15.
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: Research Department
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended September 24
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: Research Department
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended September 17
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended September 3
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: Research Department
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended August 20
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
FDA Accepts Mitapivat NDA, Grants Priority Review; Maintain Buy Rating and $93 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: Research Department